These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14647419)

  • 1. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
    Marsit CJ; Liu M; Nelson HH; Posner M; Suzuki M; Kelsey KT
    Oncogene; 2004 Jan; 23(4):1000-4. PubMed ID: 14647419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
    Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
    Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER; Ricker JL; Chen Z; Waes CV
    Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the FA/BRCA pathway in bladder cancer.
    Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
    Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the GATA genes in lung cancer.
    Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
    Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
    Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
    González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
    Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
    Gu J; Berman D; Lu C; Wistuba II; Roth JA; Frazier M; Spitz MR; Wu X
    Clin Cancer Res; 2006 Dec; 12(24):7329-38. PubMed ID: 17189404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile.
    Guzman LM; Koriyama C; Akiba S; Eizuru Y; Castillo D; Corvalan A; Aguayo FR
    Biol Res; 2007; 40(3):365-72. PubMed ID: 18449464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.
    Marsit CJ; Okpukpara C; Danaee H; Kelsey KT
    Mol Carcinog; 2005 Oct; 44(2):146-50. PubMed ID: 16013053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.